(Reuters) – Abbott Laboratories said on Wednesday its ID NOW COVID-19 rapid test showed 96.2% sensitivity and 99.5% specificity compared to lab-based molecular PCR tests, according to interim data from a study.
The results confirm the data submitted to the U.S. Food and Drug Administration in March for emergency use authorization, the medical device maker said. (https://refini.tv/2GLCVA4)
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)
